Outside-in: Overview of Delivery Method in Sirna Therapy
DOI:
https://doi.org/10.62051/w7f6xd65Keywords:
siRNA; systematic delivery; siRNA delivery vectors.Abstract
RNA interference (RNAi) is a Universal biological system based on double-strand small interference RNA (siRNA). RNAi efficiently inhibit the expression of genes based on a guiding strand. SiRNA can be applied against a broad spectrum of diseases but is limited by insufficient siRNA delivery methods. Delivery of siRNA is a challenging direction of modern molecular biology and pharmacy study; scientists aim to improve the efficiency and accuracy of siRNA-based treatment. Many approaches have been suggested to overcome challenges in effectively and safely delivering siRNA to the necessary tissues, cells, and organisms, Furthermore, endeavors have been concentrated on augmenting the effectiveness of siRNA concerning its stability, activity, specificity, and minimizing side effects. This review overviews the barriers to siRNA entrance and the challenge of siRNA delivery vectors, introduces and categorizes the currently available siRNA delivery systems including conjugate-based vectors, Lipid nanoparticle vectors, and Dendrimer vectors. And discuss the latest progress in the development of siRNA therapy. This review aims to offer a concise overview of the present advancements in siRNA delivery research and suggests potential avenues for future exploration.
Downloads
References
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391: 806 – 11.
Iwakawa, H. O., & Tomari, Y. Life of RISC: Formation, action, and degradation of RNA-induced silencing complex. Molecular cell, 2022, 82 (1), 30 – 43.
Chaplin, S. Inclisiran: a siRNA to treat hypercholesterolemia. Prescriber, 2022, 33: 23 - 24.
Kaushal, A. Innate immune regulations and various siRNA modalities. Drug Deliv. and Transl. Res 2023.
Hu, B., Zhong, L., Weng, Y. et al. Therapeutic siRNA: state of the art. Sig Transduct Target Ther 2020, 5, 101.
Ahn, I., Kang, C.S. & Han, J. Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med 2023, 55, 1283 – 1292.
Subhan, M. A., & Torchilin, V. P. siRNA-based drug design, quality, delivery, and clinical translation. Nanomedicine: nanotechnology, biology, and medicine, 2020, 29, 102239.
Wu, B., & Hur, S. How RIG-I-like receptors activate MAVS. Current opinion in virology, 2015, 12: 91 – 98.
Kaplan IM, Wadia JS, and Dowdy SF, Cationic TAT peptide transduction domain enters cells by macropinocytosis. Journal of controlled release: official journal of the Controlled Release Society 2005, 102, 247 – 53.
Thiele, D. L., & Lipsky, P. E. Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proceedings of the National Academy of Sciences, 1990, 87 (1): 83 - 87.
Demirjian, S., Ailawadi, G., Polinsky, M., Bitran, D., Silberman, S., Shernan, S. K., Burnier, M., Hamilton, M., Squiers, E., Erlich, S., Rothenstein, D., Khan, S., & Chawla, L. S. Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury. Kidney international reports, 2017, 2 (5): 836 – 843.
Geary, R.S., Henry, S.P. & Grillone, L.R. Fomivirsen. Clin Pharmacokinet 2002, 41: 255 – 260.
Schroeder, A., Levins, C. G., Cortez, C., Langer, R., & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. Journal of internal medicine, 2010, 267 (1): 9 – 21.
Suzuki, Y.; Hyodo, K.; Suzuki, T.; Tanaka, Y.; Kikuchi, H.; Ishihara, H. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. Int. J. Pharm. 2017, 519: 34 – 43.
Ramanathan RK, Hamburg SI, Borad MJ, et al. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. Cancer Res. 2013, 73 (8): LB - 289.
Springer, A. D., & Dowdy, S. F. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic acid therapeutics, 2018, 28 (3): 109 – 118.
Strat, A. L., Ghiciuc, C. M., Lupuşoru, C. E., & Mitu, F. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2016, 120 (2): 228 – 232.
Slita, A., Egorova, A., Casals, E., Kiselev, A., & Rosenholm, J. M. Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery. Asian journal of pharmaceutical sciences, 2018, 13 (6): 592 – 599.
A. Artiga, I. Serrano-Sevilla, L. De Matteis, S. G. Mitchell and J. M. de la Fuente, J. Mater. Current status and future perspectives of gold nanoparticle vectors for siRNA delivery Chem. B, 2019, 7, 876.
Gary, D. J., Puri, N., & Won, Y. Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. Journal of Controlled Release, 2007, 121 (1-2): 64 - 73.
Korzhikov-Vlakh, V., Katernuk, I., Pilipenko, I., Lavrentieva, A., Guryanov, I., Sharoyko, V., Manshina, A. A., et al. Photosensitive Poly-l-lysine/Heparin Interpol electrolyte Complexes for Delivery of Genetic Drugs. Polymers, 2020, 12 (5), 1077.
Biswas, S., & Torchilin, V. P. Dendrimers for siRNA Delivery. Pharmaceuticals (Basel, Switzerland), 2013, 6 (2): 161 – 183.
Segel, M., Lash, B., Song, J., Ladha, A., Liu, C. C., Jin, X., ... & Zhang, F. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science, 2021, 373 (6557): 882 - 889.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
